Cited by 47Amyotrophic Lateral Sclerosis ResearchBotulinum Toxin and Related Neurological DisordersNeuroscience and Neuropharmacology Research

Degeneration of serotonin neurons triggers spasticity in amyotrophic lateral sclerosis

El Oussini, Hajer, Scekic‐Zahirovic, Jelena, Vercruysse, Pauline, Marques, Christine, Dirrig‐Grosch, Sylvie, Dieterlé, Stéphane, Picchiarelli, Gina, Sinniger, Jérôme +2 more·2017·Annals of Neurology

Abstract

Objective: Spasticity occurs in a wide range of neurological diseases, including neurodegenerative diseases, after trauma, and after stroke, and is characterized by increased reflexes leading to muscle hypertonia. Spasticity is a painful symptom and can severely restrict everyday life, but might also participate in maintaining a low level of motor function in severely impaired patients. Constitutive activity of the serotonin receptors 5‐HT 2B/C is required for the development of spasticity after spinal cord injury and during amyotrophic lateral sclerosis (ALS). We sought here to provide direct evidence for a role of brainstem serotonin neurons in spasticity. Methods: SOD1(G37R) mice expressing a conditional allele of an ALS‐linked SOD1 mutation were crossed with Tph2‐Cre mice expressing Cre in serotonergic neurons. Measurement of long‐lasting reflex using electromyography, behavioral follow‐up, and histological techniques was used to characterize spasticity and motor phenotype. Results: Deleting mutant SOD1 expression selectively in brainstem serotonin neurons was sufficient to rescue loss of TPH2 immunoreactivity and largely preserve serotonin innervation of motor neurons in the spinal cord. Furthermore, this abrogated constitutive activity of 5‐HT 2B/C receptors and abolished spasticity in end‐stage mice. Consistent with spasticity mitigating motor symptoms, selective deletion worsened motor function and accelerated the onset of paralysis. Interpretation: Degeneration of serotonin neurons is necessary to trigger spasticity through the 5‐HT 2B/C receptor. The wide range of drugs targeting the serotonergic system could be useful to treat spasticity in neurological diseases. Ann Neurol 2017;82:444–456

Integrity signals

Registry

Crossref · 10.1002/ana.25030

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In mice with ALS-linked SOD1 mutations, the conditional allele of SOD1 (G37R) caused degeneration of serotonergic neurons, leading to inactivation of 5-HT2B/C receptors, with clinical manifestations such as increased muscle tone and spasticity disorders.

    “El Oussini et al. (63) found that, in mice with ALS-linked SOD1 mutations, the conditional allele of SOD1 (G37R) caused degeneration of serotonergic neurons, leading to the inactivation of 5-HT2B/C receptors, with clinical manifestations such as increased muscle tone and spasticity disorders.”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
El Oussini, H., Scekic‐Zahirovic, J., Vercruysse, P., Marques, C., Dirrig‐Grosch, S., Dieterlé, S., Picchiarelli, G., Sinniger, J., Rouaux, C., & Dupuis, L.
Affiliations
  • Faculty of medicine, Inserm UMR-S1118 France
  • Inserm (FR)
Corresponding author
Dupuis, Luc
Venue
Annals of Neurology
Publisher
Wiley
Published
2017-09
Volume
82
Issue
3
Pages
444-456
ISSN
  • 0364-5134 (ISSN-L)
  • 1531-8249
OpenAlex
W2753430298
Cited by
47
References
48
Citations by year
2026: 5 · 2025: 4 · 2024: 6 · 2023: 7 · 2022: 3 · 2021: 7 · 2020: 9 · 2019: 3 · 2018: 3
FWCI
2.86
Type
journal article
Language
en
Open access
closed
Locations
  • Annals of Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Funders
  • Fondation Thierry Latran
  • Association pour la Recherche sur la Sclérose Latérale Amyotrophique
  • European Research Council (FP7/20072013)
Topics
  • Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
  • Health Sciences › Medicine › Neurology › Botulinum Toxin and Related Neurological Disorders
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
spasticity, amyotrophic lateral sclerosis, serotonergic neurons, brainstem, SOD1, tryptophan hydroxylase 2, motor neurons, paralysis, serotonergic drugs
MeSH terms
Superoxide Dismutase-1, Alleles, Amyotrophic Lateral Sclerosis, Animals, Disease Models, Animal, Mice, Transgenic, Muscle Spasticity, Mutation, Nerve Degeneration, Mice, Serotonergic Neurons

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review